November 25, 2011 |
Sickle cell anemia causes pain, fatigue and delayed growth, all because of a lack of enough healthy red blood cells. And yet genetic mutations that cause it — recessive genes for the oxygen-carrying hemoglobin protein — have survived natural selection because they also seem to provide a natural defense against malaria. Scientists have long known this, and they have long wondered how it worked. In a paper published this month in the journal Science, researchers describe their look into how mutated hemoglobin genes defend their cells against attacks by the malaria parasite Plasmodium falciparum . Study lead author Marek Cyrklaff, an electron microscopist and molecular biologist at Heidelberg University in Germany, explained the results.
November 21, 1993 |
That spinach salad, a great source of vitamins, wasn't met with much gusto by your little eater? Here are some vegetable options: Vitamin A. Good vision; healthy skin, teeth and bones. Romaine lettuce, asparagus, green beans, tomatoes, carrots. Vitamin B family. Healthy nervous system and digestive system; development of red blood cells. Vitamin B2 (riboflavin). Spinach, asparagus, salad greens. Vitamin B5 (pantothenic acid). Cauliflower, sweet potatoes, broccoli.
June 23, 1989
Drug Reimbursements Approved: The federal Health Care Financing Administration has agreed to reimburse kidney dialysis centers when patients use Amgen Inc.'s new Epogen drug, retroactive to June 1. Epogen is the brand name for erythropoietin, a protein developed by the Thousand Oaks biotechnology company that is used to treat chronic anemia by stimulating production of red blood cells. Amgen said the U.S. will reimburse about 80% of a patient's treatment costs, with states covering the balance.
July 21, 2005 |
Genentech Inc. warned doctors of a potential anemia risk for users of its Raptiva psoriasis drug and updated earlier cautions about infections and a bleeding disorder. Two people had a form of anemia stemming from premature destruction of red blood cells during studies conducted to win Raptiva's U.S. approval in 2003, the South San Francisco-based company said in a letter to doctors posted on the Food and Drug Administration's website.
CALIFORNIA | LOCAL
February 5, 1990 |
Although the genetic defect that causes sickle cell disease has been known for more than 30 years, researchers have not been able to develop an effective therapy for the disease, which strikes one in 400 blacks born in the United States. When the oxygen content of blood from individuals with the disease falls below normal levels, as from exercise, red blood cells become deformed and impair circulation, causing damage to organs.
May 23, 1998 |
Medical experts are mystified by a rash of blood ailments that struck 14 dialysis patients during treatment at two facilities in Lincoln. The attacks, known as hemolytic episodes, stem from a breakdown of red blood cells, causing high blood pressure, chest and back pain and shortness of breath. They occurred during dialysis, a procedure to remove wastes from the blood of patients whose kidneys have failed. Four of the 14 patients were hospitalized, and one remained in critical condition.
June 25, 1998 |
Shares of Amgen Inc., the world's largest biotechnology company, rose 6.5% as the government confirmed that Medicare will pay for the company's anemia treatment Epogen even if the drug boosts red blood cells over an earlier limit. Amgen's stock rose $4.06 to close at $66.75 in Nasdaq trading. The shares earlier hit a 52-week high of $67.25. Thousand Oaks-based Amgen could sell more Epogen because the federal government changed a 1997 rule on Medicare reimbursement for the drug.